Compass Pathways plc (CMPS) — Compass Pathways issued a statement welcoming the executive order, with CEO Kabir Nath framing it as recognition of the urgency of the mental health crisis and the potential of FDA-approved psychedelics.
The company reiterated that it is running the largest classic-psychedelic trials to date and has posted two positive Phase 3 readouts for COMP360 in treatment-resistant depression. As the sector's most advanced developer, Compass is positioned to benefit directly from faster FDA review pathways.
Source: ir.compasspathways.com
For the rest of that week's sector news, read our week in review.